Physician profile
Allison Oconnor
NPI 1831975564
$2,151.22
in general payments reported to CMS, 2019-2025
29 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $27.77 · 2024: $970 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.58 | 2024-2025 | |
| Pfizer INC. | $284.47 | 2023-2025 | |
| Amgen INC. | $115.92 | 2024-2025 | Evenity, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.05 | 2024-2025 | Caplyta |
| Shield Therapeutics INC | $110.88 | 2025 | |
| Lilly USA, LLC | $110.24 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $107.70 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $79.41 | 2024-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $74.23 | 2024-2025 | Voquezna |
| Lundbeck LLC | $70.19 | 2025 | Rexulti |
| Viiv Healthcare Company | $64.73 | 2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $49.86 | 2024-2025 | |
| Organon LLC | $39.70 | 2024-2025 | Nexplanon |
| Astellas Pharma US INC | $39.02 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $30.95 | 2024-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.55 | 2023-2024 | Shingrix, Arexvy |
| Radius Health, INC. | $24.82 | 2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $24.03 | 2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $22.63 | 2025 | Unithroid |
| Noven Therapeutics, LLC | $21.86 | 2024 | Xelstrym |
| Boston Scientific Corporation | $21.35 | 2024 | Watchman Flx |
| Gilead Sciences, INC. | $20.18 | 2025 | |
| Axsome Therapeutics, INC. | $19.70 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $18.28 | 2025 | |
| Scilex Pharmaceuticals INC. | $15.28 | 2024 | |
| Exact Sciences Corporation | $14.68 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.61 | 2024 | Jardiance |
| Currax Pharmaceuticals LLC | $14.18 | 2024 | Contrave |
| Xeris Pharmaceuticals, INC. | $14.14 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.